AMWL

In the past six months, Amwell announced Q1 2026 results with $54.9 million revenue and an improved net loss of ($10.3) million, and its CFO and COO participated in the 21st Annual Needham Technology, Media & Consumer Conference. A study published in Nature Human Behaviour found that SilverCloud® by Amwell® reduced mental disorders over two years. The stock surged following a Wells Fargo analyst upgrade to a $16.00 target. Q2 2026 earnings reported an EPS of -$0.59 and revenue of $52.05 million, both beating estimates, leading to a raised 2026 revenue outlook and improved adjusted EBITDA guidance. Amwell made a grant to new employees under an inducement plan and participated in the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. The company received Frost & Sullivan's 2026 Technology Innovation Leadership Recognition and a letter of intent from the Department of Veterans Affairs to power its digital health infrastructure. Over the past three months, AMWL insiders have primarily sold shares.